Ibex AI is a leading startup in the healthcare technology sector, specializing in artificial intelligence (AI)-powered diagnostic solutions for cancer care. The company's primary focus is to assist pathologists in providing better cancer care to patients globally. Ibex AI's products are designed by pathologists for pathologists, ensuring a deep understanding of the needs and challenges in the field.

The company operates in the healthcare technology market, serving a clientele that includes top physicians, health systems, and diagnostic solution providers worldwide. Ibex AI's business model revolves around its AI-powered diagnostic platform, which is capable of detecting cancer and over a hundred other diagnostic features in various tissue types. The platform's accuracy and efficiency are clinically proven, and it offers an improved user experience.

Ibex AI's AI algorithms are developed from rich datasets extracted from over 10 million slides from multiple pathology institutes. These algorithms are trained by teams of expert pathologists using deep learning technologies, a type of AI that mimics the human brain's learning process.

The company recently raised $55 million in Series C funding to drive global adoption of AI for cancer diagnosis. The funding round was led by 83NORTH and included Sienna Venture Capital and existing investors Octopus Ventures, aMoon Fund, Planven Entrepreneur Ventures, and Dell Technologies Capital.

In terms of revenue, Ibex AI makes money by selling its AI-powered diagnostic solutions to healthcare providers and diagnostic solution providers. The company's recent funding suggests a strong market interest and potential for growth in the AI healthcare technology sector.

Keywords: Artificial Intelligence, Healthcare Technology, Cancer Diagnosis, Pathology, Deep Learning, Diagnostic Solutions, Global Health Systems, Data-Driven, Clinical Impact, Venture Capital.